0.72 USD
▼-0.10-12.28%
盘后 0.73 +1.36%
2026-11-20
市值
$4.58M
市盈率
—
EPS
-2.45
股息率
—
52 周区间
0.72 – 2.91
成交量
64.60K
Beta
-0.14
目标价
—
52W 低 0.7252W 高 2.91
价格走势
公司简介
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...